NEW YORK, Jan. 13, 2009 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (Nasdaq:SIGA), a company specializing in the development of pharmaceutical agents to fight bio-warfare pathogens, today announced it has received favorable written guidance from the European Medicines Authority (EMEA) about its proposal that its lead orthopox anti-viral drug, ST-246, should be evaluated using the Agency's procedures for the granting of a marketing authorization under exceptional circumstances, pursuant to Art. 14 (8) of regulation No. 726/2004.
